# Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

> **NCT03509246** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Ovarian Neoplasm Epithelial
- High Grade Serous Carcinoma

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin plus Bortezomib

## Key facts

- **NCT ID:** NCT03509246
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-15
- **Primary completion:** 2022-03
- **Final completion:** 2022-03
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2020-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509246, "Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03509246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*